Skip to content
Screener

Pre-Tax Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$113.38M-192%
ALN
Alnylam PharmaceuticalsALNY
$177.81M+603%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$91M+20.2%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$55.09M-11.5%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$65.54M-1,101%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$12.79M-83.4%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025Six Months Ended March 31, 2026Six Months Ended March 31, 2025
Gain on VIE's sale of IPR&D assets19,00019,000
Other, net(1,609)438(1,332)779
Total other income (expense)3,695(11,586)(8,842)(25,289)
(Loss) income before income tax expense and noncontrolling interest(137,565)369,616(109,293)194,501
Income tax expense71,753351,856
Net (loss) income including noncontrolling interest$(137,572)$367,863$(109,328)$192,645
Net loss attributable to noncontrolling interest, net of tax(4,840)(2,582)(7,409)(4,715)
Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.$(132,732)$370,445$(101,919)$197,360

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's pre-tax income?
Arrowhead Research (ARWR) reported pre-tax income of -$137.57M in Q1 2026.
How has Arrowhead Research's pre-tax income changed year-over-year?
Arrowhead Research's pre-tax income decreased by 137.2% year-over-year, from $369.62M to -$137.57M.
What is the long-term trend for Arrowhead Research's pre-tax income?
Over 4 years (2021 to 2025), Arrowhead Research's pre-tax income has grown at a -22.2% compound annual growth rate (CAGR), from -$140.85M to $51.53M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Arrowhead Research's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude